skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)

Diabetes therapy, 2024-02, Vol.15 (2), p.533-545

The Author(s) 2024 ;2024. The Author(s). ;COPYRIGHT 2024 Springer ;ISSN: 1869-6953 ;EISSN: 1869-6961 ;DOI: 10.1007/s13300-023-01526-x ;PMID: 38216831

Full text available

Citations Cited by
  • Title:
    A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)
  • Author: Hirota, Yushi ; Kakei, Yasumasa ; Imai, Junta ; Katagiri, Hideki ; Ebihara, Ken ; Wada, Jun ; Suzuki, Junichi ; Urakami, Tatsuhiko ; Omori, Takashi ; Ogawa, Wataru
  • Subjects: Blood sugar monitoring ; Cardiology ; Clinical trials ; Dextrose ; Diabetes ; Diabetes therapy ; Drug therapy ; Endocrinology ; Glucose ; Glycosylated hemoglobin ; Hypoglycemic agents ; Insulin resistance ; Internal Medicine ; Medical colleges ; Medicine ; Medicine & Public Health ; Original Research ; Pharmaceutical industry ; Type 2 diabetes
  • Is Part Of: Diabetes therapy, 2024-02, Vol.15 (2), p.533-545
  • Description: Introduction Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing the efficacy of antidiabetes drugs for these rare conditions have been limited, however. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which lower glycemia independently of insulin action, have shown efficacy for type 2 diabetes with insulin resistance. We here investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin for treatment of insulin resistance syndrome and lipoatrophic diabetes. Methods The trial was conducted at five academic centers in Japan and included seven patients with insulin resistance syndrome and one patient with lipoatrophic diabetes. Participants received 10 mg of empagliflozin daily. If the hemoglobin A 1c (HbA 1c ) level was ≥ 7.0% (52 mmol/mol) after 12 weeks, the dose was adjusted to 25 mg. The study duration was 24 weeks, and the primary outcome was the change in HbA 1c level by the end of the treatment period. Safety evaluations were performed for all participants. Results By the end of the 24-week treatment period, the mean HbA 1c level for all eight patients had decreased by 0.99 percentage points (10.8 mmol/mol) (95% confidence interval [CI], 0.59 to 1.38 percentage points, 6.6 to 14.9 mmol/mol) and the mean fasting plasma glucose concentration had declined by 63.9 mg/dL (3.55 mmol/L) (95% CI 25.5 to 102.3 mg/dL, 1.42 to 5.68 mmol/L). Continuous glucose monitoring revealed a reduction in mean glucose levels from 164.3 ± 76.1 to 137.6 ± 46.6 mg/dL (9.13 ± 4.23 to 7.65 ± 2.59 mmol/L) as well as an increase in the time in range (70–180 mg/dL) from 58.9 ± 36.1% to 70.8 ± 18.3%. Seventeen mild adverse events were recorded in five individuals throughout the study period. No severe events were reported. The mean body mass showed a slight decrease and the mean serum ketone body concentration showed a slight increase during treatment. Conclusion Our results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes. Trial Registration jRCTs2051190029 and NCT04018365.
  • Publisher: Cheshire: Springer Healthcare
  • Language: English
  • Identifier: ISSN: 1869-6953
    EISSN: 1869-6961
    DOI: 10.1007/s13300-023-01526-x
    PMID: 38216831
  • Source: Geneva Foundation Free Medical Journals at publisher websites
    PubMed Central
    SpringerOpen website
    ROAD: Directory of Open Access Scholarly Resources
    ProQuest Central
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait